Stockscreener 앱 받기
25.38
0.16%
-0.04
시간 외 거래:
25.50
0.12
+0.47%
Alumis Inc 주식(ALMS)의 최신 뉴스
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements - The Manila Times
Alumis (ALMS) details 2025 results, envudeucitinib NDA plan and cash raise - Stock Titan
A psoriasis pill hit late-stage goals; Alumis plans U.S. filing in 2026 - Stock Titan
Alumis presents phase 3 psoriasis trial data at dermatology meeting By Investing.com - Investing.com India
**Key Clinical Data to Be Revealed Soon** Biopharmaceutical company Alumis Inc. announced that the phase III clinical trial data of its lead candidate drug Envudeucitinib for the treatment of moderate-to-severe plaque psoriasis has been selected for the "Lat - Bitget
Alumis presents phase 3 psoriasis trial data at dermatology meeting - Investing.com
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting - The Manila Times
Experimental oral psoriasis drug’s Phase 3 results to debut at skin conference - Stock Titan
Alumis (NASDAQ:ALMS) Trading Down 3.5%Here's What Happened - MarketBeat
ALMS Technical Analysis & Stock Price Forecast - Intellectia AI
Wells Fargo Initiates Coverage of Alumis (ALMS) with Overweight Recommendation - MSN
Alumis Inc. (NASDAQ:ALMS) Sees Significant Drop in Short Interest - MarketBeat
Alumis Inc. (ALMS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Alumis Inc expected to post a loss of 98 cents a shareEarnings Preview - TradingView
Inflation Data: Can Alumis Inc ride the EV waveGold Moves & Low Risk Investment Opportunities - baoquankhu1.vn
Raymond James initiates coverage of Alumis (ALMS) with strong buy recommendation - MSN
Raymond James Starts ALMS (Alumis Inc. Common Stock) at Strong Buy Mar 2026 - Meyka
Alumis (NASDAQ:ALMS) Stock Price Down 6.7%Should You Sell? - MarketBeat
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Alumis (ALMS) to Release Earnings on Wednesday - MarketBeat
Assessing Alumis (ALMS) Valuation After A Strong Multi‑Month Share Price Run - Yahoo Finance
Raymond James initiates Alumis stock coverage citing psoriasis drug potential - Investing.com Nigeria
Alumis Teases TYK2 Catalysts at Leerink: Phase III Psoriasis Wins, NDA Plan and Lupus Readout Ahead - Yahoo Finance
TYK2 Validation and Expanding Indications Drive Buy Rating and $40 Price Target for Alumis - TipRanks
Certain Options of Alumis Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Phase III wins lift Alumis, Corcept shares in January - bioworld.com
Alumis to Present at the Leerink Partners Global Healthcare Conference - The Manila Times
ALMS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Alumis Inc. (NASDAQ:ALMS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference - Yahoo Finance
ALMS SEC FilingsAlumis Inc 10-K, 10-Q, 8-K Forms - Stock Titan
This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Alumis Inc. (ALMS) Investor Outlook: Analyzing a Potential 29% Upside in Biotech Innovation - DirectorsTalk Interviews
Aug Retail: Is Alumis Inc gaining market sharePortfolio Return Summary & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
This Oracle Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Stifel Nicolaus Initiates Coverage on Alumis (NASDAQ:ALMS) - MarketBeat
Stifel Initiates Alumis at Buy With $44 Price Target - marketscreener.com
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Stifel initiates Alumis stock with buy rating on TYK2 potential - Investing.com Australia
Stifel initiates Alumis stock with buy rating on TYK2 potential By Investing.com - Investing.com Canada
ALMS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
A | What is Alumis Inc.'s debt-to-equity ratio2025 Macro Impact & Fast Moving Trade Plans - mfd.ru
Big Picture: Is Alumis Inc in a consolidation phaseWeekly Trend Report & Long-Term Growth Plans - baoquankhu1.vn
Alumis Inc stock hits all-time high at 28.34 USD By Investing.com - Investing.com India
Alumis Inc stock hits all-time high at 28.34 USD - Investing.com Nigeria
Alumis (NASDAQ:ALMS) Sets New 52-Week HighStill a Buy? - MarketBeat
Risk Hedge: Is Alumis Inc gaining market shareJuly 2025 Retail & Technical Pattern Based Buy Signals - baoquankhu1.vn
Huge insider buying now at this insurance giant and 2 biotechs - MSN
Alumis Stock: Key Catalysts on the Horizon for 2026 - AD HOC NEWS
Credit Industriel ET Commercial Sells 140,000 Shares of Alumis Inc. $ALMS - MarketBeat
Why Alumis Inc. stock is trending among retail tradersProduct Launch & Weekly Watchlist for Hot Stocks - mfd.ru
1.20%
0.06%
자본화:
|
볼륨(24시간):